P2RY12 and acute coronary syndrome: Potent P2Y12 inhibitors reduce the incidence of cardiovascular events in patients with acute coronary syndromes, and we recently showed that prasugrel, as compared to ticagrelor, also prevents PCI-induced endothelial dysfunction.